1450 Opella Healthcare Brazil Ltda
Opella's Brazilian entity makes and supplies over-the-counter medicines, vitamins and self-care products, drawing on 13 manufacturing sites and a portfolio of 100 brands across more than 100 countries.
1450 Opella Healthcare Brazil Ltda is the Brazilian legal entity of Opella, a global consumer healthcare company. Opella separated from Sanofi in April 2025 to become an independent company, and its operations run across more than 100 countries, supported by 13 manufacturing sites and a workforce of approximately 11,000 people. The company produces and distributes over-the-counter medicines, vitamins, minerals and supplements, and other self-care products to some 500 million consumers worldwide.
The group's portfolio comprises 100 brands, among them Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. Product development and pharmaceutical manufacturing are backed by four specialised science and innovation centres, working across consumer health science, self-care product development and health literacy.
Following separation, CD&R holds a controlling 50% stake in Opella, with Sanofi retaining 48.2% and Bpifrance 1.8%. The stated mission, "Health in Your Hands", frames a focus on consumer-centred innovation and simpler self-care. Community health programmes have reached 1.7 million beneficiaries since 2022, and the company has set a target of improving the health literacy of 50 million people annually.